Business Segments · Sales to customers (Note 9)
Innovative Medicine — Sales to customers (Note 9)
Johnson & Johnson Innovative Medicine — Sales to customers (Note 9) decreased by 2.1% to $15.43B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.2%, from $13.87B to $15.43B. Over 4 years (FY 2021 to FY 2025), Innovative Medicine — Sales to customers (Note 9) shows an upward trend with a 4.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2021
Last reportedQ1 2026Apr 22, 2026
Rolls up toTotal Revenue
How to read this metric
Higher sales indicate strong market adoption and competitive success of the segment's product portfolio.
Detailed definition
Measures the total revenue generated from external customers by the Innovative Medicine segment. This is the primary top...
Peer comparison
Equivalent to 'Segment Revenue' or 'Net Sales' for pharmaceutical segments at peer companies.
Metric ID:
jnj_segment_innovative_medicine_sales_to_customers_note_9Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.92B | $12.92B | $12.92B | $12.87B | $13.32B | $13.21B | $13.16B | $13.41B | $13.73B | $13.89B | $13.72B | $13.56B | $14.49B | $14.58B | $14.33B | $13.87B | $15.20B | $15.56B | $15.76B | $15.43B |
| QoQ Change | — | +0.0% | +0.0% | -0.4% | +3.5% | -0.8% | -0.4% | +1.9% | +2.4% | +1.2% | -1.2% | -1.2% | +6.8% | +0.6% | -1.7% | -3.2% | +9.6% | +2.4% | +1.3% | -2.1% |
| YoY Change | — | — | — | — | +3.1% | +2.3% | +1.9% | +4.2% | +3.1% | +5.1% | +4.2% | +1.1% | +5.5% | +4.9% | +4.4% | +2.3% | +4.9% | +6.7% | +10.0% | +11.2% |
Range$12.87B – $15.76B
CAGR+3.8%
Avg YoY Growth+4.7%
Median YoY Growth+4.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported innovative medicine — sales to customers (note 9) of $15.43B in Q1 2026.
- How has Johnson & Johnson's innovative medicine — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's innovative medicine — sales to customers (note 9) increased by 11.2% year-over-year, from $13.87B to $15.43B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — sales to customers (note 9) has grown at a 4.0% compound annual growth rate (CAGR), from $51.68B to $60.40B.
- What does innovative medicine — sales to customers (note 9) mean?
- Total revenue earned from selling products to external customers in the Innovative Medicine segment.